CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

Published Date: 08 Feb 2026

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New surgical method shows promising results for cervical cancer treatment

2.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

5.

Can Prior Authorization Be Better With Artificial Intelligence?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot